Anika Therapeutics (ANIK)
NASDAQ:ANIK
Want to see ANIK full AI Analyst Report?
ANIK Stock Chart & Stats
$9.75
$0.27(1.72%)
At close: 4:00 PM EST
$9.75
$0.27(1.72%)
Day’s Range― - ―
52-Week Range$7.87 - $16.24
Previous CloseN/A
Volume22.29K
Average Volume (3M)174.95K
Market Cap
$191.33M
Enterprise Value$178.05M
Total Cash (Recent Filing)$41.02M
Total Debt (Recent Filing)$25.74M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 05, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding13,305,624
10 Day Avg. Volume181,118
30 Day Avg. Volume174,954
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.96
Price to Sales (P/S)1.22
P/FCF Ratio31.59
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit2.61
Enterprise Value/Ebitda-26.85
Forecast
1Y Price Target
$17.00Price Target Upside74.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$118.61M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum & Product AdoptionSustained surgeon adoption of Integrity (35% procedure growth and 3,000+ cases) signals durable commercial traction and growing installed base. A rising procedure cadence supports recurring consumable sales, improves revenue visibility across channels, and anchors long‑term organic growth.
Gross Margin ExpansionA meaningful ~8 percentage point gross margin lift reflects manufacturing productivity and better mix, creating structural operating leverage. Higher sustainable gross margins enhance the company’s ability to fund R&D and commercial investment while improving potential adjusted EBITDA conversion over multi‑year horizons.
Balance Sheet Liquidity & Low LeverageA strong cash balance and minimal leverage provide strategic optionality to fund commercialization, regulatory programs, and capital projects without near‑term refinancing risk. This financial flexibility supports execution through multi‑quarter regulatory timelines and product rollouts.
Bears Say
Recurring Losses & Negative MarginsDespite acceptable top‑line and gross margins, recurring operating and net losses limit retained earnings and shareholder returns. Persistent unprofitability constrains reinvestment flexibility and heightens reliance on cash reserves or capital markets during extended commercialization or regulatory intervals.
Inconsistent Cash GenerationA sharp FCF decline (~76% year‑over‑year) and historically volatile cash generation complicate multi‑period planning. Unstable free cash flow increases the risk that funding for R&D, regulatory studies, or commercial ramps will require tradeoffs or external financing during slower demand or unexpected spends.
Regulatory Timing RiskA PMA deficiency for Hyalofast and open interactions with the FDA create material execution risk for a significant product opportunity. Uncertain Hyalofast and CINGAL timelines could delay U.S. commercialization inflection points and compress projected multi‑year revenue gains tied to these approvals.
Anika Therapeutics News
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $7.87 and its highest was $16.24 in the past 12 months.
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is $191.33M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 62 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Apr 29, 2026. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.34.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 13,305,624 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of $0.27 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went down -18.807%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in ANIK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anika Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (74.36% Upside)
$17.00 (74.36% Upside)
Blogger Sentiment
Bullish
ANIK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $223.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.14%
12-Months-Change
Fundamentals
Return on Equity
-7.74%
Trailing 12-Months
Asset Growth
-5.89%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
ANIK Company Deck
ANIK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights meaningful commercial momentum (13% revenue growth), strong operational improvements (gross margin up ~8 percentage points and adjusted EBITDA lift), accelerating adoption of Integrity and international product strength, supported by a clean balance sheet and active share repurchase. Key near-term concerns include higher operating expenses (notably a onetime $4.9M severance), regulatory timelines for Hyalofast and CINGAL that remain uncertain, OEM channel timing and mix variability, and caution that Q1 margin levels may not be fully sustained quarter-to-quarter. Overall, the positives around revenue growth, margin improvement, pipeline progress and liquidity outweigh the manageable near-term risks and uncertainties.View all ANIK earnings summariesANIK Stock 12 Month Forecast
Average Price Target
$17.00
▲(74.36% Upside)
Technical Analysis
Ownership Overview
5.48% Insiders
12.34% Mutual Funds
20.41% Other Institutional Investors
49.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---